2 results about "Mouse strain" patented technology

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The invention discloses a construction method and application of an animal model with insufficient bladder activity and fibrosis, and belongs to the technical field of biology. The construction method comprises the following steps: constructing a Krt20-Cre-tdTomato mouse strain Krt20-Cre-tdTomato through a gene editing technology, and specifically, inserting a Cre-2A-tdTomato-Wpre-pA sequence into a first exon of a Krt20 gene by adopting a CRISPR / Cas9 mediated homologous recombination technology, and constructing the Krt20-Cre-tdTomato mouse strain which can be used as an animal model with insufficient bladder activity and fibrosis. The method is applied to the research of screening medicines for treating bladder activity deficiency and bladder fibrosis. According to the method, the problems that the existing lower urinary tract symptom modeling process is complicated and the model types are insufficient are solved, and the constructed bladder activity deficiency and fibrosis animal model can provide a basis and a preclinical animal model for screening potential drug targets.